scholarly journals BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection

2015 ◽  
Vol 112 (12) ◽  
pp. 1921-1928 ◽  
Author(s):  
M Schirripa ◽  
F Bergamo ◽  
C Cremolini ◽  
M Casagrande ◽  
S Lonardi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Liver Resection ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Ras Mutations ◽  
Colorectal Cancer Patients

scholarly journals KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan: Molecular spectrum, frequency and distribution pattern

2019 ◽  
Author(s):  
Muhammad Awidi ◽  
Nidaa Ababneh ◽  
Maha Shomaf ◽  
Feras Al Fararjeh ◽  
Laila Owaidi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Distribution Pattern ◽  
Cancer Patients ◽  
Molecular Spectrum ◽  
Kras Mutations ◽  
Exon 2 ◽  
Ras Mutations ◽  
Colorectal Cancer Patients ◽  
Kras Exon

Abstract Background A constitutively active RAS protein in the absence of stimulation of the epidermal growth factor receptor (EGFR) is the result of mutations in KRAS and NRAS genes. Mutations in the KRAS exon 2 and outside exon 2 have been found to predict the resistance to anti-EGFR monoclonal therapy. A substantial proportion of metastatic colorectal cancer cases (mCRC) exhibit RAS mutations outside KRAS exon 2, particularly in KRAS exon 3 and 4 and NRAS exons 2, 3. No data about RAS mutations outside KRAS exon 2 are available for Jordanian patients with mCRC. We aim to study the molecular spectrum, frequency, and distribution pattern of KRAS and NRAS mutations in Jordanian patients with mCRC. Methods A cohort of 190 Jordanian metastatic colorectal cancer patients were enrolled in the trial. We detected mutations in exon 2 of the KRAS and NRAS gene as well as mutations outside of exon 2 using the StripAssay technique. The KRAS StripAssay covered 29 mutations and 22 NRAS mutations. Results Mutations were observed in 92 (48.42%) cases, and KRAS exon 2 accounted for 76 cases (83.69%). KRAS G12D was the most common mutation, occurring in 18 cases, followed by KRAS G12A in 16 cases, and G12T in 13 cases. Mutations outside of KRAS exon 2 represented 16.3% of the mutated cases. Among those, 6 cases (6.48%) carried mutations in NRAS exon 2, 3 and 10 cases (10.87%) in KRAS exon 3 and 4. Conclusion The frequency of NRAS and KRAS mutations outside of exon 2 appears to be higher in Jordanian patients in comparison with patients from western countries. KRAS mutations outside of exon 2 should be tested routinely to identify patients who should not be treated with anti-EGFR antibodies.

Analysis of survival and prognostic factors in metastatic colorectal cancer patients treated with first line bevacizumab.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15009-e15009 ◽  
Author(s):  
Nazim Demircan ◽  
Faysal Dane ◽  
Mehmet Akif Ozturk ◽  
Mehmet Besiroglu ◽  
Nalan Babacan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Prognostic Factors ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
First Line ◽  
Right Colon Cancer ◽  
Kras Status ◽  
Colorectal Cancer Patients ◽  
Left Colon Cancer

e15009 Background: Colorectal cancer is a major cause of mortality worldwide. Survival has been improved by usage of bevacizumab. Our study aimed to analyze survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab. Methods: Files of patients were examined retrospectively and 360 patients treated with first-line bevacizumab were included. Data regarding age, gender, family history, location of the primary, histopathology, KRAS status, surgery and chemotherapy were acquired from the files. Overall response rates (ORR) to chemotherapy, progression and exitus dates or dates of last examination were recorded. Median progression-free and overall survival (PFS and OS) were calculated. Survival was analyzed with Kaplan-Meier method. Log-rank test and Cox regression model were used for univariate and multivariate analysis, respectively. Results: 201 (%55,8) of the patients were male and 159 (%44,2) were female. Median age at the time of the diagnosis was 59.5. 260 patients (%72,2) had initially stage IV disease. KRAS was mutant in 125 patients (%34,7). Median PFS was 8.5 months, median OS was 25.3 months and ORR was %51,4. Median PFS was 8.2 and 9.5 months, median OS was 30.4 and 28.1 months, ORR was %62,6 and %58.4 in KRAS wild type and mutant groups, respectively. In patients with left colon cancer median PFS and OS (9.6 and 27.1 months) were superior compared to patients with right colon cancer (7.3 and 19.4 months) (p = 0.005 and 0.016, respectively). Location of the primary, histopathologic grade, primary surgery, metastasectomy and KRAS status affected overall survival significantly (p < 0.05) in univariate analysis. In multivariate analysis, histopathologic grade (p = 0.034) and metastasectomy (p = 0.001) were independent prognostic factors. Conclusions: In our study, response rates and survival of metastatic colorectal cancer patients treated with first-line bevacizumab were similar to previous studies. Left colon cancer patients had superior median PFS and OS compared to right colon cancer patients as shown in recent studies. Histopathologic grade and metastasectomy were independent prognostic factors in correlation with literature.

Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients

Tumor Biology ◽  
2012 ◽  
Vol 33 (6) ◽  
pp. 1829-1835 ◽  
Author(s):  
Elisabeth Pérez-Ruiz ◽  
A. Rueda ◽  
T. Pereda ◽  
J. Alcaide ◽  
D. Bautista ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Amino Acid ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Amino Acid Substitutions ◽  
Ras Mutations ◽  
Colorectal Cancer Patients

scholarly journals RAS mutations testing and choice of first-line treatment for metastatic colorectal cancer patients in our institute

2017 ◽  
Vol 28 ◽  
pp. ix98
Author(s):  
Takashi Iwata ◽  
Eiki Ojima ◽  
Tomomi Mohri ◽  
Tomohumi Noguchi ◽  
Kiyoshi Hashimoto ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Line Treatment ◽  
First Line ◽  
Ras Mutations ◽  
Colorectal Cancer Patients ◽  
First Line Treatment

Should Hepatic Metastatic Colorectal Cancer Patients with Extrahepatic Disease Undergo Liver Resection/Ablation?

2009 ◽  
Vol 16 (11) ◽  
pp. 3064-3069 ◽  
Author(s):  
Jerome Byam ◽  
Nathaniel P. Reuter ◽  
Charles E. Woodall ◽  
Charles R. Scoggins ◽  
Kelly M. McMasters ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Resection ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Extrahepatic Disease ◽  
Undergo Liver Resection ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document